Volanesorsen
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Volanesorsen: From Familial Chylomicronemia Syndrome to Megaloblastic Anemia
One-Sentence Summary
Volanesorsen is an antisense oligonucleotide directed against APOC3 mRNA, originally developed to lower ApoC-III and triglyceride levels in familial chylomicronemia syndrome (per mechanism described in the evidence pack). The TxGNN model predicts it may be effective for Megaloblastic Anemia, but currently no clinical trials and no publications support this direction, and the drug is not yet marketed in the EU.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Familial Chylomicronemia Syndrome (FCS) — inferred from the mechanism-of-action note in the evidence pack; no formal EU regulatory record is available |
| Predicted New Indication | Megaloblastic Anemia |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
The original_moa field in the evidence pack is marked as a data gap, so no formally structured mechanism-of-action data is available. However, the rationale accompanying the top-ranked prediction states that Volanesorsen is an APOC3 mRNA antisense oligonucleotide that reduces ApoC-III and triglycerides, and is used to treat familial chylomicronemia syndrome — a lipid metabolism disorder.
Megaloblastic anemia is primarily caused by vitamin B12 or folate metabolic abnormalities. According to the evidence pack’s own mechanistic assessment, there is no known biological pathway connecting lipoprotein/triglyceride metabolism to B12/folate-dependent erythropoiesis. The rationale explicitly describes this mechanistic link as “weak,” meaning the prediction currently rests solely on knowledge-graph pattern similarity rather than a plausible pharmacological rationale.
This pattern is consistent across all ten of TxGNN’s top-ranked predictions for this drug: each is explicitly flagged in the evidence pack as having a weak, indirect, or absent mechanistic connection to Volanesorsen’s known lipid-lowering activity, and none are backed by clinical trials or literature. This should be read as an early-stage, exploratory signal rather than a validated repurposing hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Volanesorsen currently holds 0 marketing authorizations in the EU registry captured by this evidence pack (market_status: Not marketed). No authorization records, product names, or approved indication texts are available for extraction.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction is supported only by TxGNN model output (L5) with zero clinical trials and zero publications, and the evidence pack’s own rationale rates the mechanistic link between APOC3 inhibition and megaloblastic anemia as weak or absent.
- A Blocking-severity data gap (DG001: EU/TFDA label warnings and contraindications) means the candidate cannot yet pass the S1 safety screening stage, and the drug is not currently marketed in the EU.
To proceed, the following is needed:
- Official product label / SmPC warnings and contraindications (resolves DG001, Blocking)
- Confirmed, structured mechanism-of-action and original indication documentation (resolves DG002)
- Preclinical or mechanistic studies establishing a plausible pathway between ApoC-III/triglyceride modulation and megaloblastic anemia pathophysiology
- Generation of at least preliminary clinical or non-clinical evidence before advancing this candidate beyond decision stage S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.